1. |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
|
2. |
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
|
3. |
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223): 514-523.
|
4. |
Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J, 2020, 55(6): 2000562.
|
5. |
Pan A, Liu L, Wang C, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA, 2020, 323(19): 1-9.
|
6. |
Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med, 2020, 201(11): 1380-1388.
|
7. |
Qin C, Zhou LQ, Hu ZW, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis, 2020, 71(15): 762-768.
|
8. |
Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest, 2020, 130(5): 2620-2629.
|
9. |
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, 2020, 368: m1091.
|
10. |
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720.
|
11. |
Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med, 2020, 201(11): 1372-1379.
|
12. |
Liu F, Xu AF, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis, 2020, 95: 183-191.
|
13. |
Flores-Torres AS, Salinas-Carmona MC, Salinas E, et al. Eosinophils and respiratory viruses. Viral Immunol, 2019, 32(5): 198-207.
|
14. |
Tiwary M, Rooney RJ, Liedmann S, et al. Eosinophil responses at the airway epithelial barrier during the early phase of influenza A virus infection in C57BL/6 mice. Cells, 2021, 10(3): 509.
|
15. |
Barton LM, Duval EJ, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol, 2020, 153(6): 725-733.
|
16. |
姚小红, 李廷源, 何志承, 等. 新型冠状病毒肺炎(COVID-19)三例遗体多部位穿刺组织病理学研究. 中华病理学杂志, 2020, 49(5): 411-417.
|
17. |
Djangang NN, Peluso L, Talamonti, M, et al. Eosinopenia in COVID-19 patients: a retrospective analysis. Microorganisms, 2020, ; 8(12): 1929.
|
18. |
Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol, 2020, 92(6): 577-583.
|
19. |
Borges do Nascimento IJ, Cacic N, et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med, 2020, 9(4): 941.
|
20. |
杨硕, 苏斌涛, 陈菁, 等. 糖皮质激素对新型冠状病毒肺炎患者 T 淋巴细胞亚群的影响. 中国呼吸与危重监护杂志, 2021, 20(3): 159-163.
|
21. |
Delshad M, Tavakolinia N, Sigaroodi AP, et al. The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. Int Immunopharmacol, 2021, 95: 107586.
|
22. |
徐佳丽, 胡蓓蓓, 茅秋霞, 等. 新型冠状病毒肺炎患者的静脉血栓栓塞症风险评估与抗凝治疗. 中国呼吸与危重监护杂志, 2021, 20(2): 101-105.
|
23. |
Kassin MT, Varble N, Blain M, et al. Generalized chest CT and lab curves throughout the course of COVID-19. Sci Rep, 2021, 11(1): 6940.
|
24. |
Ali A, Noman M, Guo Y, et al. Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. Sci Rep, 2021, 11(1): 5975.
|
25. |
Canzano P, Brambilla M, Porro B, et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl Sci, 2021, 6(3): 202-218.
|
26. |
Zuo ZH, Wu T, Pan LY, et al. Modalities and mechanisms of treatment for coronavirus disease 2019. Front Pharmacol, 2021, 11: 583914.
|
27. |
Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med, 2020, 46(2): 315-328.
|
28. |
Noreen S, Maqbool I, Madni A. Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol, 2021, 894: 173854.
|
29. |
Sarma A, Christenson S, Mick E, et al. COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone[EB/OL]. Res Sq [Preprint]. [2021-01-14]. rs. 3. rs-141578. https://assets.researchsquare.com/files/rs-141578/v1_stamped.pdf.
|